{"anticipatedPostingDate":"2028-06","denomUnitsSelected":"Participants","description":"The PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent anticancer therapy, based on investigator assessment (after that used for PFS) or death, whichever comes first.","reportingStatus":"NOT_POSTED","timeFrame":"Approximately 60 months","title":"Progression-Free Survival After First Subsequent Therapy (PFS2)","type":"SECONDARY"}